Saturday 17 November 2018 ,
Latest News
  • BNP seeks EC’s intervention in stopping arrest of its activists
  • Bus fire kills 40 in Zimbabwe
  • 11 killed as Cyclone Gaja ravages India's Tamil Nadu
  • BNP to start interviewing nomination seekers Sunday
  • Action to be taken for violation of electoral code of conduct: Monirul
  • Deployment of army ‘10 days’ ahead of polls
  • Myanmar blames Bangladesh for repatriation failure
  • Rohingya repatriation: US for ‘go-and-see’ visits
  • Child killed, 6 burnt in Jatrabari gas cylinder blast
  • Oikyafront, BNP-led alliance yet to decide on seat sharing
  • Zuckerberg should 'step down' from Facebook, tech pioneer says
17 October, 2018 12:57:13 AM / LAST MODIFIED: 17 October, 2018 01:50:56 PM

Print

20 medicines recalled for raw material impurities

Drug admin orders Incepta, ACME, Popular, Drug Int’l, Renata, Healthcare to withdraw blood pressure control medicines
STAFF REPORTER
20 medicines recalled for raw material impurities

The drug administration has asked six pharmaceutical companies to withdraw over 20 medicines used for blood pressure control after cancer creating compounds were found in raw materials. Directorate General of Drug Administration (DGDA), the drug regulatory authority of Bangladesh, in an order issued on Sunday asked Incepta Pharmaceuticals, ACME Laboratories Ltd , Popular Pharmaceuticals, Drug International, Renata Pharmaceuticals and Healthcare Pharmaceuticals to withdraw the medicines manufactured from the raw material ‘Valsartan’, which were produced by Zhuhai  Rundu Pharmaceutical Co Ltd and Zhejiang Tianyu Pharmaceutical Co Ltd of China.

Talking to The Independent, DGDA Director Ruhul Amin said the raw material named ‘Valsartan’ from two Chinese manufacturers contained traces of probable carcinogenic (cancer creating) compound NDMA (N-Nitrosodimethylamine).

As the medicines made using this active ingredient from the two Chinese companies were withdrawn in European countries, the DGDA has also ordered the recall of such medicines from the Bangladesh market, added Amin.

The DGDA ordered its field officials to confiscate the medicines from the market within the next seven days. The recalled medicines include Amlosartan tablet of Incepta; Valtin, Co-Valtin tablets of ACME; Amlovas vs tablets of Popular; Tab,Av-5,10, 5/80 of Drug International; Valdipin FC of Renata; and Disys, Co-Disys tablets of Healthcare.  

Earlier in July, several heart drugs containing Valsartan were recalled in Europe and Asia after residues of a substance were found in its supplies that could cause cancer, according to international media. A Chinese company voluntarily informed the European Medicines Agency (EMA) that it had identified N-nitrosodimethylamine

(NDMA), a chemical that might lead to cancer, in its Valsartan provided to the European market.  As a result, medicines containing Valsartan made by the Chinese company were recalled. Valsartan, a drug first developed by Novartis to treat high blood pressure and heart failure, has already gone off patent and is used in many medicines made by several drugmakers. US Food and Drug Administration also joined European countries to recall it in July because of the health risk.

SR

 

 

 

 

Comments

Poll
Today's Question »
Do you agree with Election Commissioner Kabita Khanam that a cent per cent fair election is not possible anywhere in the world?
 Yes
 No
 No Comment
Yes 69.7%
No 24.2%
No Comment 6.1%
Video
More Bangladesh Stories

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting